For the Media

The information in this section is intended for media professionals who are interested in learning more about infertility and EMD Serono's role in supporting women and couples with fertility health concerns.

This section contains fact sheets and recent press releases which include consumer-oriented information on infertility.

Recent Press Releases:

To view the download, you need Adobe® Acrobat® Reader® installed. Don't have Adobe Acrobat Reader on your computer? Download it free, here.

Adobe Acrobat Reader is a registered trademark of Adobe Systems Incorporated.

You can learn more about infertility and treatment options by calling Fertility LifeLines™ at 1-866-LETS-TRY (1-866-538-7879) or visiting www.fertilitylifelines.com. It's free and confidential.

For information about EMD Serono, Inc., please visit www.emdserono.com.

Feel free to contact us for more information about EMD Serono Reproductive Health products and activities. We are also happy to put you in touch with corporate spokespeople and fertility health experts.

Media Contact:

Colleen Minden
Director of Communications, Endocrinology
EMD Serono, Inc.
One Technology Place
Rockland, MA 02370
TEL 1-781-681-2192
FAX 1-781-681-2927

Important: Please do not use this contact information for reporting Adverse Events. For medical information and adverse event reporting, please call 1-888-ASK-SERO (888-275-7376).

Gonal-f® Has Helped Many Couples.

Learn more about this fertility medication.

Say What?

With so many unfamiliar new terms, learning about fertility can feel like you're learning another language. Get the translation by using our glossary.

FIND A FERTILITY SPECIALIST

Enter your Zip code to find a fertility treatment specialist or fertility clinic in your area:

Important Considerations:
Gonal-f® RFF Pen (follitropin alfa injection) is indicated for the induction of ovulation and pregnancy in the oligo-anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® RFF Pen is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program. Gonal-f® RFF Pen (follitropin alfa injection) should only be prescribed by physicians specializing in fertility or reproductive health. Gonal-f® is a potent gonadotropic substance capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications, and multiple births. Gonal-f® is contraindicated in women who exhibit prior hypersensitivity to FSH preparations, primary gonadal failure, uncontrolled thyroid or adrenal dysfunction and pregnancy. Nursing women should not use Gonal-f®. Common side effects include headache, abdominal pain, enlarged abdomen, and injection site disorders. For complete product details, see full prescribing information.

Important Considerations:
Women: Gonal-f® (follitropin alfa for injection) is indicated for the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program.
Men: Gonal-f® (follitropin alfa for injection) is indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure. Gonal-f® (follitropin alfa for injection) should only be prescribed by physicians who are thoroughly familiar with infertility problems and their management. Gonal-f® is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications. Gonal-f® is contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor; and in women who exhibit abnormal uterine bleeding of undetermined origin, ovarian cyst or enlargement of undetermined origin and pregnancy. Women who are pregnant or nursing should not use Gonal-f®. The most common side effects in patients using Gonal-f® include headache, ovarian cysts, nausea and upper respiratory infections in women and in men, acne, breast pain and growth, and fatigue. Injection site reactions were also reported. Reports of multiple births have been associated with Gonal-f® treatment. For complete product details, see the full prescribing information.

For complete product details, please read the Prescribing Information offered below.


© EMD Serono, Inc. CIM Last Update 2008-09-16
This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

This site contains information that is intended for US residents only. Canadian residents should consult the EMD Serono Canada Inc. Web site at www.emdserono.ca for information on products and services approved in Canada.

EMD Serono

Close

Please wait... loading

View the Full Glossary